von Willebrand Disease (vWD) Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2032

von Willebrand Disease (vWD) Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2032

Summary

The prevalence of vWD is increasing at a steady rate, in line with population growth in the 3MM, at an AGR of 0.61%.

Currently, the treatment regimen for vWD in the 3MM is mostly limited to DDAVP and coagulation factor VIII + vWF complex.

There are several unmet needs in this space, including the need for better diagnostic tools for vWD and improved therapies for severe vWD.

The vWD late-stage R&D pipeline is focused on developing vWF recombinant for pediatric use, RNA oligonucleotide therapy BT-200.

Significant growth is expected throughout the forecast period as the vWD population steadily increases and novel therapies enter the market.

Key Highlights

Report deliverables include a Pdf report and Excel-based forecast model
Forecast includes three countries: US, Germany, and the UK
Forecasts cover three time points: base year, 5-year, and 10-year

Scope

• Overview of vWD, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized vWD therapeutics market revenue in 3MM (US, Germany and the UK), annual cost of therapy and treatment usage pattern in 2022 and forecast for 10 years to 2032; forecast covers three time points: base year, 5-year, and 10-year.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the vWD therapeutics market.
• Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for vWD treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the 3MM vWD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the vWD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the vWD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Please not this is delivered as a zip file.